Synthesized peptide derived from human p21 Cip1 (Phospho Ser129)

This antibody detects endogenous levels of p21 Cip1 (Phospho Ser129) Rabbit pAb at Human, Mouse.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):EGsPG

CDKN1A CAP20 CDKN1 CIP1 MDA6 PIC1 SDI1 WAF1

Cyclin-dependent kinase inhibitor 1 (CDK-interacting protein 1) (Melanoma differentiation-associated protein 6) (MDA-6) (p21)

CDKN1A ;
CAP20 ;
CDKN1 ;
CIP1 ;
MDA6 ;
PIC1 ;
SDI1 ;
WAF1 ;
Cyclin-dependent kinase inhibitor 1 ;
CDK-interacting protein 1 ;
Melanoma differentiation-associated protein 6 ;
MDA-6 ;
p21 ;

cyclin dependent kinase inhibitor 1A(CDKN1A) Homo sapiens This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-cyclin-dependent kinase2 or -cyclin-dependent kinase4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen, a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of cyclin-dependent kinase2, and may be instrumental in the execution of apoptosis following caspase activation. Mice that lac

Function:May be the important intermediate by which p53 mediates its role as an inhibitor of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression.,induction:By p53, mezerein (antileukemic compound) and interferon beta.,PTM:Phosphorylation of Thr-145 by Akt or of Ser-146 by PKC impairs binding to PCNA.,similarity:Belongs to the CDI family.,tissue specificity:Expressed in all adult human tissues, with 5-fold lower levels observed in the brain.,

Cytoplasm . Nucleus .

>>Endocrine resistance ;
>>Platinum drug resistance ;
>>ErbB signaling pathway ;
>>HIF-1 signaling pathway ;
>>FoxO signaling pathway ;
>>Cell cycle ;
>>p53 signaling pathway ;
>>PI3K-Akt signaling pathway ;
>>Cellular senescence ;
>>JAK-STAT signaling pathway ;
>>Oxytocin signaling pathway ;
>>Parathyroid hormone synthesis, secretion and action ;
>>Cushing syndrome ;
>>Hepatitis C ;
>>Hepatitis B ;
>>Human cytomegalovirus infection ;
>>Human papillomavirus infection ;
>>Human T-cell leukemia virus 1 infection ;
>>Kaposi sarcoma-associated herpesvirus infection ;
>>Epstein-Barr virus infection ;
>>Pathways in cancer ;
>>Transcriptional misregulation in cancer ;
>>Viral carcinogenesis ;
>>Proteoglycans in cancer ;
>>MicroRNAs in cancer ;
>>Colorectal cancer ;
>>Renal cell carcinoma ;
>>Pancreatic cancer ;
>>Endometrial cancer ;
>>Glioma ;
>>Prostate cancer ;
>>Thyroid cancer ;
>>Basal cell carcinoma ;
>>Melanoma ;
>>Bladder cancer ;
>>Chronic myeloid leukemia ;
>>Small cell lung cancer ;
>>Non-small cell lung cancer ;
>>Breast cancer ;
>>Hepatocellular carcinoma ;
>>Gastric cancer